Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J van Helden

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
NPJ Vaccines|March 28, 2018
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicityMargherita Coccia, Catherine Collignon, Caroline Hervé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal CancerSophie L Gerritse, Erik J van Helden, Anne I J Arens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
[<sup>89</sup>Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Journal of Hypertension|December 4, 2021
A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severitySakir Akin, Paula Schriek, Cees van Nieuwkoop, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2020
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Cell Stem Cell|May 28, 2020
Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart DiseaseElisa Giacomelli, Viviana Meraviglia, Giulia Campostrini, et al.
Journal for Immunotherapy of Cancer|April 17, 2023
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cellsMary J van Helden, Seline A Zwarthoff, Roel J Arends, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
NPJ Vaccines|March 28, 2018
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicityMargherita Coccia, Catherine Collignon, Caroline Hervé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal CancerSophie L Gerritse, Erik J van Helden, Anne I J Arens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
[<sup>89</sup>Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Journal of Hypertension|December 4, 2021
A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severitySakir Akin, Paula Schriek, Cees van Nieuwkoop, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2020
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerE J van Helden, S G Elias, S L Gerritse, et al.
Cell Stem Cell|May 28, 2020
Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart DiseaseElisa Giacomelli, Viviana Meraviglia, Giulia Campostrini, et al.
Journal for Immunotherapy of Cancer|April 17, 2023
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cellsMary J van Helden, Seline A Zwarthoff, Roel J Arends, et al.
Pageof 6